Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

• Status: RECRUITING
• Trial end date: 2028-08-31

Summary

This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).

• Phase: PHASE2

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China
• Collaborators: Afliated Hospital of North Sichuan Medical College; Baoding First Central Hospital; Changzhi Medical College; North China University of Science and Technology; Shenzhen Second People's Hospital; The Affiliated Hospital of Nantong University; The Affiliated Hospital of Qingdao University; The First Affiliated Hospital of Bengbu Medical University; The Second Affiliated Hospital of Dalian Medical University; Tianjin Hospital of ITCWM-Nankai Hospital; Weifang People's Hospital
• Treatments: Dexamethasone